Skip to content

Serum Procalcitonin Study in the Management of Ventilated Patients

Clinical Utility of Serum Procalcitonin in the Management of Ventilator-Associated Pneumonia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00726167
Enrollment
29
Registered
2008-07-31
Start date
2008-09-30
Completion date
2014-08-31
Last updated
2016-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator Associated Pneumonia

Keywords

Ventilator associated Pneumonia, mechanically ventilated, procalcitonin, pneumonia scores

Brief summary

The purpose of this study is to test a new method for diagnosing and monitoring Ventilator-Associated Pneumonia, which is a major killer among ICU patients. The method requires analysis of a small amount of the patient's blood for concentration of a hormone called Procalcitonin.

Detailed description

Ventilator-associated pneumonia is a leading cause of mortality in critically ill patients. The purpose of this study is to evaluate the relationship between the onset/progress/resolution of pneumonia and the levels of Procalcitonin, a prohormone whose concentrations fluctuate in response to bacterial infection.

Interventions

Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.

Sponsors

University of Missouri-Columbia
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Are willing to give or who's proxy is willing to consent to be a study subject * Are at least 18 years of age; * Who are mechanically ventilated surgical intensive care unit patients.

Exclusion criteria

* Participation in any investigational device or drug trial within 30 days prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Correlation of Procalcitonin concentration with the LungGuardian-derived Pneumonia Score in mechanically ventilated surgical intensive care unit patients. Using the data collected a positive and negative predictive value will be calculated.Once daily

Secondary

MeasureTime frame
antibiotic status (appropriateness, effectiveness, discontinuation criteria)Once daily
intubation dateOnce daily
microbiology dataOnce daily
PCT levelsOnce daily
pneumonia-related symptoms (including tracheal secretion character, body temperature, oxygenation, and WBC counts)Once daily

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026